Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Identifieur interne : 000900 ( PubMed/Corpus ); précédent : 000899; suivant : 000901Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Auteurs : Emeline Colomba ; Gwénaël Le Teuff ; Tim Eisen ; Grant D. Stewart ; Kate Fife ; James Larkin ; Andrea Biondo ; Lisa Pickering ; Anandagopal Srinivasan ; Helen Boyle ; Lisa Derosa ; Cora N. Sternberg ; Federica Recine ; Christy Ralph ; Carolina Saldana ; Philippe Barthélémy ; Jean Christophe Bernhard ; Howard Gurney ; Gregory Verhoest ; Elodie Vauleon ; Pierre Bigot ; Julien Berger ; Christian Pfister ; Gwenaelle Gravis ; Jean-Michel Rodier ; Stéphane Culine ; Armelle Caty ; Frederic Rolland ; Franck Priou ; Bernard Escudier ; Laurence AlbigesSource :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2017.
English descriptors
- KwdEn :
- Adult, Aged, Angiogenesis Inhibitors (therapeutic use), Antineoplastic Agents (therapeutic use), Carcinoma, Renal Cell (drug therapy), Carcinoma, Renal Cell (mortality), Carcinoma, Renal Cell (secondary), Enzyme Inhibitors (therapeutic use), Female, Humans, Kaplan-Meier Estimate, Kidney Neoplasms (drug therapy), Kidney Neoplasms (mortality), Kidney Neoplasms (secondary), Male, Middle Aged, Molecular Targeted Therapy (methods), Retrospective Studies, Survival Analysis, TOR Serine-Threonine Kinases (antagonists & inhibitors), Time Factors, Treatment Failure.
- MESH :
- chemical , antagonists & inhibitors : TOR Serine-Threonine Kinases.
- chemical , therapeutic use : Angiogenesis Inhibitors, Antineoplastic Agents, Enzyme Inhibitors.
- drug therapy : Carcinoma, Renal Cell, Kidney Neoplasms.
- methods : Molecular Targeted Therapy.
- mortality : Carcinoma, Renal Cell, Kidney Neoplasms.
- secondary : Carcinoma, Renal Cell, Kidney Neoplasms.
- Adult, Aged, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Retrospective Studies, Survival Analysis, Time Factors, Treatment Failure.
Abstract
Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.
DOI: 10.1016/j.ejca.2017.03.011
PubMed: 28549248
Links to Exploration step
pubmed:28549248Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.</title><author><name sortKey="Colomba, Emeline" sort="Colomba, Emeline" uniqKey="Colomba E" first="Emeline" last="Colomba">Emeline Colomba</name><affiliation><nlm:affiliation>Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Le Teuff, Gwenael" sort="Le Teuff, Gwenael" uniqKey="Le Teuff G" first="Gwénaël" last="Le Teuff">Gwénaël Le Teuff</name><affiliation><nlm:affiliation>Department of Biostatistics and Epidemiology, Gustave Roussy, INSERM U1018, CESP, Université Paris-Saclay, Villejuif, F-94805, France.</nlm:affiliation></affiliation></author><author><name sortKey="Eisen, Tim" sort="Eisen, Tim" uniqKey="Eisen T" first="Tim" last="Eisen">Tim Eisen</name><affiliation><nlm:affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Stewart, Grant D" sort="Stewart, Grant D" uniqKey="Stewart G" first="Grant D" last="Stewart">Grant D. Stewart</name><affiliation><nlm:affiliation>Edinburgh Urological Cancer Group, University of Edinburgh, Western General Hospital, Edinburgh, UK; Academic Urology Group, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Fife, Kate" sort="Fife, Kate" uniqKey="Fife K" first="Kate" last="Fife">Kate Fife</name><affiliation><nlm:affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation><nlm:affiliation>Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Biondo, Andrea" sort="Biondo, Andrea" uniqKey="Biondo A" first="Andrea" last="Biondo">Andrea Biondo</name><affiliation><nlm:affiliation>Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Pickering, Lisa" sort="Pickering, Lisa" uniqKey="Pickering L" first="Lisa" last="Pickering">Lisa Pickering</name><affiliation><nlm:affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Srinivasan, Anandagopal" sort="Srinivasan, Anandagopal" uniqKey="Srinivasan A" first="Anandagopal" last="Srinivasan">Anandagopal Srinivasan</name><affiliation><nlm:affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Boyle, Helen" sort="Boyle, Helen" uniqKey="Boyle H" first="Helen" last="Boyle">Helen Boyle</name><affiliation><nlm:affiliation>Medical Oncology, Centre Léon Bérard, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Derosa, Lisa" sort="Derosa, Lisa" uniqKey="Derosa L" first="Lisa" last="Derosa">Lisa Derosa</name><affiliation><nlm:affiliation>Medical Oncology, Istituto Toscano Tumori, Pisa, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Sternberg, Cora N" sort="Sternberg, Cora N" uniqKey="Sternberg C" first="Cora N" last="Sternberg">Cora N. Sternberg</name><affiliation><nlm:affiliation>Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Recine, Federica" sort="Recine, Federica" uniqKey="Recine F" first="Federica" last="Recine">Federica Recine</name><affiliation><nlm:affiliation>Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ralph, Christy" sort="Ralph, Christy" uniqKey="Ralph C" first="Christy" last="Ralph">Christy Ralph</name><affiliation><nlm:affiliation>Department of Medical Oncology, Institute of Cancer Studies & Pathology University of Leeds, Leeds, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Saldana, Carolina" sort="Saldana, Carolina" uniqKey="Saldana C" first="Carolina" last="Saldana">Carolina Saldana</name><affiliation><nlm:affiliation>Medical Oncology, Hôpital Henri Mondor Créteil AP-HP, France.</nlm:affiliation></affiliation></author><author><name sortKey="Barthelemy, Philippe" sort="Barthelemy, Philippe" uniqKey="Barthelemy P" first="Philippe" last="Barthélémy">Philippe Barthélémy</name><affiliation><nlm:affiliation>Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bernhard, Jean Christophe" sort="Bernhard, Jean Christophe" uniqKey="Bernhard J" first="Jean Christophe" last="Bernhard">Jean Christophe Bernhard</name><affiliation><nlm:affiliation>Department of Urology, CHU de Bordeaux, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gurney, Howard" sort="Gurney, Howard" uniqKey="Gurney H" first="Howard" last="Gurney">Howard Gurney</name><affiliation><nlm:affiliation>Faculty of Medicine and Health Sciences Macquarie University, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Verhoest, Gregory" sort="Verhoest, Gregory" uniqKey="Verhoest G" first="Gregory" last="Verhoest">Gregory Verhoest</name><affiliation><nlm:affiliation>Department of Urology, CHU de Rennes, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Vauleon, Elodie" sort="Vauleon, Elodie" uniqKey="Vauleon E" first="Elodie" last="Vauleon">Elodie Vauleon</name><affiliation><nlm:affiliation>Medical Oncology, Centre Eugène Marquis, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bigot, Pierre" sort="Bigot, Pierre" uniqKey="Bigot P" first="Pierre" last="Bigot">Pierre Bigot</name><affiliation><nlm:affiliation>Medical Oncology, CHU d'Angers Angers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Berger, Julien" sort="Berger, Julien" uniqKey="Berger J" first="Julien" last="Berger">Julien Berger</name><affiliation><nlm:affiliation>Department of Urology, CHU Dupuytren, Limoges, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pfister, Christian" sort="Pfister, Christian" uniqKey="Pfister C" first="Christian" last="Pfister">Christian Pfister</name><affiliation><nlm:affiliation>Department of Urology, CHU Charles Nicolle, Rouen, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gravis, Gwenaelle" sort="Gravis, Gwenaelle" uniqKey="Gravis G" first="Gwenaelle" last="Gravis">Gwenaelle Gravis</name><affiliation><nlm:affiliation>Medical Oncology, Institut Paoli-Calmettes, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rodier, Jean Michel" sort="Rodier, Jean Michel" uniqKey="Rodier J" first="Jean-Michel" last="Rodier">Jean-Michel Rodier</name><affiliation><nlm:affiliation>Medical Oncology, Hôpital Bichat Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Culine, Stephane" sort="Culine, Stephane" uniqKey="Culine S" first="Stéphane" last="Culine">Stéphane Culine</name><affiliation><nlm:affiliation>Medical Oncology, Hôpital Saint Louis Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Caty, Armelle" sort="Caty, Armelle" uniqKey="Caty A" first="Armelle" last="Caty">Armelle Caty</name><affiliation><nlm:affiliation>Medical Oncology, Hopital privée la Louvière Lille, France; Medical Oncology, Centre Oscar Lambret Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rolland, Frederic" sort="Rolland, Frederic" uniqKey="Rolland F" first="Frederic" last="Rolland">Frederic Rolland</name><affiliation><nlm:affiliation>Medical Oncology, Institut René Gauducheau Saint Herblain, France.</nlm:affiliation></affiliation></author><author><name sortKey="Priou, Franck" sort="Priou, Franck" uniqKey="Priou F" first="Franck" last="Priou">Franck Priou</name><affiliation><nlm:affiliation>Medical Oncology, Centre Hospitalier de Vendée La Roche sur Yon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name><affiliation><nlm:affiliation>Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Albiges, Laurence" sort="Albiges, Laurence" uniqKey="Albiges L" first="Laurence" last="Albiges">Laurence Albiges</name><affiliation><nlm:affiliation>Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: laurence.albiges@gustaveroussy.fr.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28549248</idno><idno type="pmid">28549248</idno><idno type="doi">10.1016/j.ejca.2017.03.011</idno><idno type="wicri:Area/PubMed/Corpus">000900</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000900</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.</title><author><name sortKey="Colomba, Emeline" sort="Colomba, Emeline" uniqKey="Colomba E" first="Emeline" last="Colomba">Emeline Colomba</name><affiliation><nlm:affiliation>Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Le Teuff, Gwenael" sort="Le Teuff, Gwenael" uniqKey="Le Teuff G" first="Gwénaël" last="Le Teuff">Gwénaël Le Teuff</name><affiliation><nlm:affiliation>Department of Biostatistics and Epidemiology, Gustave Roussy, INSERM U1018, CESP, Université Paris-Saclay, Villejuif, F-94805, France.</nlm:affiliation></affiliation></author><author><name sortKey="Eisen, Tim" sort="Eisen, Tim" uniqKey="Eisen T" first="Tim" last="Eisen">Tim Eisen</name><affiliation><nlm:affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Stewart, Grant D" sort="Stewart, Grant D" uniqKey="Stewart G" first="Grant D" last="Stewart">Grant D. Stewart</name><affiliation><nlm:affiliation>Edinburgh Urological Cancer Group, University of Edinburgh, Western General Hospital, Edinburgh, UK; Academic Urology Group, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Fife, Kate" sort="Fife, Kate" uniqKey="Fife K" first="Kate" last="Fife">Kate Fife</name><affiliation><nlm:affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation><nlm:affiliation>Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Biondo, Andrea" sort="Biondo, Andrea" uniqKey="Biondo A" first="Andrea" last="Biondo">Andrea Biondo</name><affiliation><nlm:affiliation>Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Pickering, Lisa" sort="Pickering, Lisa" uniqKey="Pickering L" first="Lisa" last="Pickering">Lisa Pickering</name><affiliation><nlm:affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Srinivasan, Anandagopal" sort="Srinivasan, Anandagopal" uniqKey="Srinivasan A" first="Anandagopal" last="Srinivasan">Anandagopal Srinivasan</name><affiliation><nlm:affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Boyle, Helen" sort="Boyle, Helen" uniqKey="Boyle H" first="Helen" last="Boyle">Helen Boyle</name><affiliation><nlm:affiliation>Medical Oncology, Centre Léon Bérard, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Derosa, Lisa" sort="Derosa, Lisa" uniqKey="Derosa L" first="Lisa" last="Derosa">Lisa Derosa</name><affiliation><nlm:affiliation>Medical Oncology, Istituto Toscano Tumori, Pisa, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Sternberg, Cora N" sort="Sternberg, Cora N" uniqKey="Sternberg C" first="Cora N" last="Sternberg">Cora N. Sternberg</name><affiliation><nlm:affiliation>Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Recine, Federica" sort="Recine, Federica" uniqKey="Recine F" first="Federica" last="Recine">Federica Recine</name><affiliation><nlm:affiliation>Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ralph, Christy" sort="Ralph, Christy" uniqKey="Ralph C" first="Christy" last="Ralph">Christy Ralph</name><affiliation><nlm:affiliation>Department of Medical Oncology, Institute of Cancer Studies & Pathology University of Leeds, Leeds, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Saldana, Carolina" sort="Saldana, Carolina" uniqKey="Saldana C" first="Carolina" last="Saldana">Carolina Saldana</name><affiliation><nlm:affiliation>Medical Oncology, Hôpital Henri Mondor Créteil AP-HP, France.</nlm:affiliation></affiliation></author><author><name sortKey="Barthelemy, Philippe" sort="Barthelemy, Philippe" uniqKey="Barthelemy P" first="Philippe" last="Barthélémy">Philippe Barthélémy</name><affiliation><nlm:affiliation>Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bernhard, Jean Christophe" sort="Bernhard, Jean Christophe" uniqKey="Bernhard J" first="Jean Christophe" last="Bernhard">Jean Christophe Bernhard</name><affiliation><nlm:affiliation>Department of Urology, CHU de Bordeaux, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gurney, Howard" sort="Gurney, Howard" uniqKey="Gurney H" first="Howard" last="Gurney">Howard Gurney</name><affiliation><nlm:affiliation>Faculty of Medicine and Health Sciences Macquarie University, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Verhoest, Gregory" sort="Verhoest, Gregory" uniqKey="Verhoest G" first="Gregory" last="Verhoest">Gregory Verhoest</name><affiliation><nlm:affiliation>Department of Urology, CHU de Rennes, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Vauleon, Elodie" sort="Vauleon, Elodie" uniqKey="Vauleon E" first="Elodie" last="Vauleon">Elodie Vauleon</name><affiliation><nlm:affiliation>Medical Oncology, Centre Eugène Marquis, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bigot, Pierre" sort="Bigot, Pierre" uniqKey="Bigot P" first="Pierre" last="Bigot">Pierre Bigot</name><affiliation><nlm:affiliation>Medical Oncology, CHU d'Angers Angers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Berger, Julien" sort="Berger, Julien" uniqKey="Berger J" first="Julien" last="Berger">Julien Berger</name><affiliation><nlm:affiliation>Department of Urology, CHU Dupuytren, Limoges, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pfister, Christian" sort="Pfister, Christian" uniqKey="Pfister C" first="Christian" last="Pfister">Christian Pfister</name><affiliation><nlm:affiliation>Department of Urology, CHU Charles Nicolle, Rouen, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gravis, Gwenaelle" sort="Gravis, Gwenaelle" uniqKey="Gravis G" first="Gwenaelle" last="Gravis">Gwenaelle Gravis</name><affiliation><nlm:affiliation>Medical Oncology, Institut Paoli-Calmettes, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rodier, Jean Michel" sort="Rodier, Jean Michel" uniqKey="Rodier J" first="Jean-Michel" last="Rodier">Jean-Michel Rodier</name><affiliation><nlm:affiliation>Medical Oncology, Hôpital Bichat Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Culine, Stephane" sort="Culine, Stephane" uniqKey="Culine S" first="Stéphane" last="Culine">Stéphane Culine</name><affiliation><nlm:affiliation>Medical Oncology, Hôpital Saint Louis Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Caty, Armelle" sort="Caty, Armelle" uniqKey="Caty A" first="Armelle" last="Caty">Armelle Caty</name><affiliation><nlm:affiliation>Medical Oncology, Hopital privée la Louvière Lille, France; Medical Oncology, Centre Oscar Lambret Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rolland, Frederic" sort="Rolland, Frederic" uniqKey="Rolland F" first="Frederic" last="Rolland">Frederic Rolland</name><affiliation><nlm:affiliation>Medical Oncology, Institut René Gauducheau Saint Herblain, France.</nlm:affiliation></affiliation></author><author><name sortKey="Priou, Franck" sort="Priou, Franck" uniqKey="Priou F" first="Franck" last="Priou">Franck Priou</name><affiliation><nlm:affiliation>Medical Oncology, Centre Hospitalier de Vendée La Roche sur Yon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name><affiliation><nlm:affiliation>Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Albiges, Laurence" sort="Albiges, Laurence" uniqKey="Albiges L" first="Laurence" last="Albiges">Laurence Albiges</name><affiliation><nlm:affiliation>Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: laurence.albiges@gustaveroussy.fr.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Carcinoma, Renal Cell (drug therapy)</term><term>Carcinoma, Renal Cell (mortality)</term><term>Carcinoma, Renal Cell (secondary)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Kidney Neoplasms (drug therapy)</term><term>Kidney Neoplasms (mortality)</term><term>Kidney Neoplasms (secondary)</term><term>Male</term><term>Middle Aged</term><term>Molecular Targeted Therapy (methods)</term><term>Retrospective Studies</term><term>Survival Analysis</term><term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term><term>Time Factors</term><term>Treatment Failure</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Antineoplastic Agents</term><term>Enzyme Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Molecular Targeted Therapy</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Survival Analysis</term><term>Time Factors</term><term>Treatment Failure</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28549248</PMID><DateCreated><Year>2017</Year><Month>05</Month><Day>26</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.</ArticleTitle><Pagination><MedlinePgn>55-62</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(17)30829-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2017.03.011</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2-10.9) and 22.9 months (95% CI: 17.8-49.2) versus 1.9 months (95% CI: 1.0-6.0) and 3.2 months (95% CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.</AbstractText><CopyrightInformation>Copyright © 2017. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colomba</LastName><ForeName>Emeline</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Teuff</LastName><ForeName>Gwénaël</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, Gustave Roussy, INSERM U1018, CESP, Université Paris-Saclay, Villejuif, F-94805, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisen</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Grant D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Edinburgh Urological Cancer Group, University of Edinburgh, Western General Hospital, Edinburgh, UK; Academic Urology Group, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fife</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larkin</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biondo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickering</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Anandagopal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Oncology, Centre Léon Bérard, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derosa</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Oncology, Istituto Toscano Tumori, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sternberg</LastName><ForeName>Cora N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recine</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>Christy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Institute of Cancer Studies & Pathology University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saldana</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Oncology, Hôpital Henri Mondor Créteil AP-HP, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barthélémy</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernhard</LastName><ForeName>Jean Christophe</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Urology, CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurney</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhoest</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology, CHU de Rennes, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vauleon</LastName><ForeName>Elodie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medical Oncology, Centre Eugène Marquis, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Oncology, CHU d'Angers Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Urology, CHU Dupuytren, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfister</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Urology, CHU Charles Nicolle, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravis</LastName><ForeName>Gwenaelle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Oncology, Institut Paoli-Calmettes, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodier</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Medical Oncology, Hôpital Bichat Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Culine</LastName><ForeName>Stéphane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology, Hôpital Saint Louis Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caty</LastName><ForeName>Armelle</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology, Hopital privée la Louvière Lille, France; Medical Oncology, Centre Oscar Lambret Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolland</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medical Oncology, Institut René Gauducheau Saint Herblain, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priou</LastName><ForeName>Franck</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medical Oncology, Centre Hospitalier de Vendée La Roche sur Yon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escudier</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albiges</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: laurence.albiges@gustaveroussy.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-angiogenic</Keyword><Keyword MajorTopicYN="N">Chromophobe RCC</Keyword><Keyword MajorTopicYN="N">Metastatic</Keyword><Keyword MajorTopicYN="N">Non–clear cell RCC</Keyword><Keyword MajorTopicYN="N">VEGF</Keyword><Keyword MajorTopicYN="N">mTOR</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>03</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28549248</ArticleId><ArticleId IdType="pii">S0959-8049(17)30829-8</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2017.03.011</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000900 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000900 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28549248
|texte= Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28549248" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |